Intestine Cancer Therapeutics Global Market Report 2024

The intestine cancer therapeutics market size has grown strongly in recent years. It will grow from $12.8 billion in 2023 to $14 billion in 2024 at a compound annual growth rate (CAGR) of 9.4%. The growth observed in the historical period can be attributed to several factors, including advancements in medical research, a rise in cancer incidence, the utilization of chemotherapy and radiation therapies, initiatives focused on screening and early detection, and discoveries in genetic and biomarker research.

The intestine cancer therapeutics market size is expected to see strong growth in the next few years. It will grow to $19.36 billion in 2028 at a compound annual growth rate (CAGR) of 8.4%. The anticipated growth in the forecast period can be attributed to advancements in immunotherapy, the progress in precision medicine and personalized therapies, the emergence of targeted therapies, the integration of artificial intelligence (AI), and the adoption of patient-centric approaches. Notable trends expected in the forecast period include the utilization of liquid biopsy technologies, continued emphasis on precision medicine and biomarker research, the exploration of combination therapies, a focus on patient-centric care and supportive therapies, and the increasing adoption of minimally invasive surgical techniques.

The anticipated increase in the prevalence of hereditary colorectal cancer syndromes is poised to drive the growth of the intestine cancer therapeutics market. These syndromes, genetic conditions that elevate the risk of colorectal cancer, play a pivotal role in intestinal cancer therapeutics by providing information linked to specific genetic mutations significantly amplifying the likelihood of colorectal cancer development. As per the World Health Organization's projections in July 2023, the prevalence of hereditary colorectal cancer is expected to witness a substantial rise by 2040, with an estimated 3.2 million new cases and 1.6 million deaths annually. This represents a 63% increase in new cases and a 73% surge in fatalities compared to current rates. Consequently, the escalating prevalence of hereditary colorectal cancer syndromes is a key driver of the intestine cancer therapeutics market.

The growing demand for personalized medicine is anticipated to propel the growth of the intestine cancer therapeutics market. Personalized medicine, tailoring medical decisions and drug therapies to a patient's unique characteristics, enhances treatment effectiveness and minimizes side effects in intestine cancer therapeutics. In 2022, the Food and Drug Administration's Center for Drug Evaluation and Research (CDER) approved 37 new molecular entities (NMEs), with approximately 34%, or 12 of them, classified as personalized medicines by the Personalized Medicine Coalition (PMC). This underscores the rising demand for personalized medicine, driving the growth of the intestine cancer therapeutics market.

The anticipated growth of the intestine cancer therapeutics market is expected to face challenges due to the high cost of cancer treatment. The substantial financial burden associated with diagnosing and treating cancer can impact therapies for intestinal cancer, affecting financial responsibility, access to care, and health disparities. According to the American Cancer Society Cancer Action Network (ACS CAN) in December 2022, survivors' expenses, including follow-up care costs and addressing the late and long-term effects of cancer, averaged $1,881 per survivor. Moreover, 51% of surveyed patients reported incurring medical debt related to cancer. Consequently, the high cost of cancer treatment is hindering the growth of the intestine cancer therapeutics market.

Major companies operating in the intestine cancer therapeutics market are actively developing innovative products, such as Lonsurf, and securing approvals to broaden their customer bases, increase sales, and boost revenue. Lonsurf, a combination of trifluridine and tipiracil, received approval from the US Food and Drug Administration in August 2023 for treating adult patients with metastatic colorectal cancer. Taiho Oncology Inc., the US-based pharmaceutical company behind Lonsurf, aims to provide patients with metastatic colorectal cancer and other eligible cancers a new treatment option to potentially enhance outcomes and improve quality of life.

In September 2022, CytoReason Ltd, an Israel-based biotechnology company, joined forces with Pfizer Inc. for AI-driven drug discovery and development. Pfizer's drug research activities will incorporate CytoReason's AI technologies under this collaboration, which may be valued up to $110 million over the next five years. The agreement involves Pfizer contributing $20 million in stock, offering options to license CytoReason's platform and disease models, and providing additional project support. Pfizer Inc., a US-based pharmaceutical company, contributes to the advancements in intestine cancer therapeutics through this collaboration.

Major companies operating in the intestine cancer therapeutics market report are Pfizer Inc., Johnson & Johnson Private Limited, Roche Holding AG, AbbVie Inc., Bayer AG, Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company, Abbott Laboratories, GSK plc., Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Merck KGaA, Mylan N.V., Astellas Pharma Inc., Daiichi Sankyo Company Limited, Eisai Co. Ltd., Boehringer Ingelheim International GmbH, Sun Pharmaceutical Industries Ltd., Ipsen Pharma, Hikma Pharmaceuticals plc, Amneal Pharmaceuticals LLC, Cipla Inc., Aurobindo Pharma Limited, Lupin Limited.

Asia-Pacific was the largest region in the intestine cancer therapeutics market in 2023. North America is expected to be the fastest-growing region in the forecast period. The regions covered in the intestine cancer therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa The countries covered in the intestine cancer therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The intestine cancer therapeutics market includes revenues earned by entities by provide services such as colonoscopies and fecal occult blood tests, clinical trials, supportive care, genetic testing and counseling, and psychological support. The market value includes the value of related goods sold by the service provider or included within the service offering. The intestine cancer therapeutics market also includes sales of Alymsys, Avastin (bevacizumab), bevacizumab, Camptosar (irinotecan hydrochloride), capecitabine, cetuximab, angiogenesis inhibitors, multikinase inhibitors, epigenetic agents, and supportive care products. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The primary types of treatments for intestine cancer therapeutics include immunotherapy, chemotherapy, and other modalities. Immunotherapy, a form of cancer treatment, harnesses the body's immune system to combat cancer cells. These therapeutic options are distributed through various channels such as hospital pharmacies, online pharmacies, and retail pharmacies. They are commonly utilized by institutions such as hospitals, homecare facilities, specialty centers, and others.

The intestine cancer therapeutics market research report is one of a series of new reports that provides intestine cancer therapeutics market statistics, including intestine cancer therapeutics industry global market size, regional shares, competitors with an intestine cancer therapeutics market share, detailed intestine cancer therapeutics market segments, market trends and opportunities, and any further data you may need to thrive in the intestine cancer therapeutics industry. This intestine cancer therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.